IP Library › Granted Patent US 12,465,658
Granted Patent B2
US 12,465,658 · App. 18/405,670 · Granted Nov 11, 2025

Eye drop composition

Inventors: Nesva Goris (Leawood, KS); Johan Neyts (Leawood, KS); Erwin Blomsma (Leawood, KS); Stefaan Wera (Leawood, KS); Ainola Billiet (Leawood, KS); Joeri Auwerx (Leawood, KS); Veerle Debeurme (Leawood, KS); Maryline Roe (Leawood, KS); Pascal Puig (Leawood, KS)
Assignee: Aratana Therapeutics, Inc.
A61K49/0004A61K9/0048A61K31/305A61K31/522A61K47/24A61K47/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,465,658
App. No.
18/405,670
Granted
Nov 11, 2025
Kind
B2
Abstract

The present invention relates to an eye-drop composition comprising 2-amino-9-[[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-1,9-dihydro-6H-Purin-6-one, and the use thereof for the diagnosis and treatment of herpetic eye infections in companion animals.

Claims (25)

1 . A composition comprising:

at least 0.1% w/v 2-amino-9-[[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-1, 9-dihydro-6H-Purin-6-one; and

at least 10-99% w/v of a cyclodextrin.

2 . The composition of claim 1 , wherein the composition is an aqueous solution.

3 . The composition of claim 1 , wherein the composition is an ophthalmic solution.

4 . The composition of claim 1 , wherein the cyclodextrin is hydroxypropyl beta-cyclodextrin.

5 . The composition of claim 1 , wherein the composition further comprises at least 0.005% w/v thiomersal.

6 . The composition of claim 1 , wherein the composition comprises at least 10% w/v of a cyclodextrin.

7 . The composition of claim 1 , wherein the composition comprises at least 15% w/v of a cyclodextrin.

8 . The composition of claim 1 , wherein the composition comprises at least 20% w/v of a cyclodextrin.

9 . The composition of claim 1 , wherein the composition comprises at least 50% w/v of a cyclodextrin.

10 . The composition of claim 1 , wherein the pH of the composition is between pH 5 and pH 8.5.

11 . The composition of claim 1 , wherein the composition has an osmotic pressure between 200 mOsm/L and 400 mOsm/L.

12 . The composition of claim 1 , wherein the composition further comprises a tonicity adjusting agent, optionally, dextrose, glycerin, mannitol, potassium chloride, sodium chloride, or a phosphate buffer.

13 . The composition of claim 1 , wherein the composition is sterile.

14 . A method for the treatment of an ocular herpetic infection in an animal comprising administering the composition of claim 1 to an animal in need thereof.

15 . The method of claim 14 , wherein the animal is a feline, canine, or an equine animal.

16 . The method of claim 14 , wherein the ocular herpetic infection is a feline herpes virus infection.

17 . The method of claim 14 , wherein the method comprises applying the composition onto the eye two or three times per day.

18 . The method of claim 14 , wherein the method comprises applying the composition onto the eye for 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 days.

19 . The method of claim 14 , wherein the method comprises applying the composition directly to the eye, optionally to the cornea.

20 . A method of diagnosing an ocular infection comprising

(a) administering the composition of claim 1 to an animal; and

(b) determining if clinical symptoms are improved,

wherein improvement of clinical symptoms within 1 to 7 days is an indication of the presence of a herpes virus infection.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2024
From: GORIS, NESVA; NEYTS, JOHAN; BLOMSMA, ERWIN; WERA, STEFAAN; BILLIET, AINOLA; AUWERX, JOERI; DEBEURME, VEERLE; ROE, MARYLINE; PUIG, PASCAL
To: ARATANA THERAPEUTICS NV
Reel/Frame 066038/0391 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2024
From: ARATANA THERAPEUTICS NV
To: ARATANA THERAPEUTICS, INC.
Reel/Frame 066038/0426 →
Continuity (4)
Division 17205673 · Mar 18, 2021
Continuation 14828365 · Aug 17, 2015
Continuation 14373322
Related Publication 20240148909A1 · May 9, 2024
References Cited (41)
US 9040699B2 · Kiss et al. · 2015 [cited by applicant]
US 9107943B2 · Goris et al. · 2015 [cited by applicant]
US 10967074B2 · Goris et al. · 2021 [cited by applicant]
US 20150098904A1 · Goris et al. · 2015 [cited by applicant]
US 20150352118A1 · Goris et al. · 2015 [cited by applicant]
US 20210205478A1 · Goris et al. · 2021 [cited by applicant]
CN 101433721A · 2009 [cited by applicant]
EA 200100316A · 2002 [cited by applicant]
EP 0502690A2 · 1992 [cited by applicant]
EP 0649840A1 · 1995 [cited by applicant]
EP 0675123A1 · 1995 [cited by applicant]
EP 0890574A1 · 1999 [cited by applicant]
JP H0578357A · 1994 [cited by applicant]
JP H0680670A · 1994 [cited by applicant]
JP H0841035A · 1996 [cited by applicant]
JP 2004026695A · 2004 [cited by applicant]
RU 2414898C1 · 2011 [cited by applicant]
WO 2002005822A2 · 2002 [cited by applicant]
WO 2010042030A1 · 2010 [cited by applicant]
WO 2013107515A1 · 2013 [cited by applicant]
Loftsson, T., and E. Stefansson. “Effect of cyclodextrins on topical drug delivery to the eye.” Drug development and industrial pharmacy, (1997), vol. 23, No. 5: 473-482. [cited by applicant]
International Search Report re International Application No. PCT/EP2012/050843, dated Aug. 28, 2012, in 3 pages. [cited by applicant]
Chen, Wei, et al. “An improved synthesis of 9-[2-(diethoxyphosphonomethoxy) ethyl] adenine and its analogues with other purine bases utilizing the Mitsunobu reaction.” Nucleosides, Nucleotides & Nucleic Acids, (1996), v… [cited by applicant]
Csuk, René, and Anja Kern. “Synthesis of spacered cyclopropyl nucleoside analogues as potential antiviral agents.” Tetrahedron, (1999), vol. 55, No. 28: 8409-8422. [cited by applicant]
Gallos, John K., et al. “Carbocyclic nucleoside precursors by intramolecular cyclopropanation of sugar-derived diazo compounds.” Tetrahedron Letters, (2001), vol. 42, No. 42: 7489-7491. [cited by applicant]
Gianni, Michael H., et al. “The role of the generalized anomeric effect in the conformational analysis of 1, 3-dioxacycloalkanes. Conformational analysis of 3, 5-dioxabicyclo [5.1. 0] octanes and 3, 5, 8-trioxabicyclo [… [cited by applicant]
Khlebnikova, Tatiana B., et al. “Synthesis of new chiral phosphorous-and nitrogen-containing ligands from resin acids.” Chirality: The Pharmacological, Biological, and Chemical Consequences of Molecular Asymmetry, (2004… [cited by applicant]
Swamy, KC Kumara, et al. “Mitsunobu and related reactions: advances and applications.” Chemical reviews, (2009), vol. 109, No. 6: 2551-2651. [cited by applicant]
Onishi, Tomoyuki, et al. “Synthesis and antiviral activity of novel anti-VZV 5-substituted uracil nucleosides with a cyclopropane sugar moiety.” Journal of medicinal chemistry, (2000), vol. 43, No. 2: 278-282. [cited by applicant]
Park, Ah-Young, et al. “Synthesis of enantiomerically pure d-and I-bicyclo [3.1. 0] hexenyl carbanucleosides and their antiviral evaluation.” Bioorganic & medicinal chemistry, (2011), vol. 19, No. 13: 3945-3955. [cited by applicant]
Sekiyama, Takaaki, et al. “Synthesis and antiviral activity of novel acyclic nucleosides: discovery of a cyclopropyl nucleoside with potent inhibitory activity against herpesviruses.” Journal of medicinal chemistry, (19… [cited by applicant]
International Search Report of International Patent Application PCT/EP2012/050843, provided by the International Search Authority, mailed Sep. 4, 2012, 3 pages. [cited by applicant]
Itahashi, Motoki, et al. “A-5021: A New Acyclovir Analogue Inhibits Murine Herpetic Keratitis.” Cornea, (2008), vol. 27, No. 3: 334-338. (Abstract). [cited by applicant]
Iwayama, Satoshi et al. “Antiherpesvirus activities of (1′ S, 2′ R)-9-{[1′, 2′-bis (hydroxymethyl) cycloprop-1′-yl] methyl} guanine (A-5021) in cell culture.” Antimicrobial agents and chemotherapy, (1998), vol. 42, No. … [cited by applicant]
Loftssona, Thorsteinn, and Tomi Järvinen. “Cyclodextrins in ophthalmic drug delivery.” Advanced drug delivery reviews, (1999), vol. 36, No. 1: 59-79. (Abstract). [cited by applicant]
Neyts, Johan, et al. “Anti-herpesvirus activity of (1′ S, 2′ R)-9-[1′, 2′-bis (hydroxymethyl)-cycloprop-1′-yl] methyl] guanine (A-5021) in vitro and in vivo.” Antiviral research, (2001), vol. 49, No. 2: 115-120. (Abstra… [cited by applicant]
Iwayama, Satoshi, et al. “Evaluation of anti-herpesvirus activity of (1′ S, 2′ R)-9-[[1′, 2′-bis (hydroxymethyl) cycloprop-1′-yl] methyl] guanine (A-5021) in mice.” Antiviral research, (1999), vol. 42, No. 2: 139-148. [cited by applicant]
Kaur, Indu P., et al. “Role of cyclodextrins in ophthalmics.” Current drug delivery, (2004), vol. 1, No. 4: 351-360. [cited by applicant]
Ozhegov's Explanatory Dictionary online (2008-2009, found from the Internet (Nov. 5, 2015) URL: http://slovarozhegova.ru/word.php?wordid=6534). [cited by applicant]
Kershaw et al., “Detection of equine herpesvirus type 2 (EHV-2) in horses with keratoconjunctivitis”, Virus Research, vol. 80, 2001, pp. 93-99 (Abstract). [cited by applicant]
Ledbetter et al., “Experimental reactivation of latent canine herpesvirus-1 and induction of recurrent ocular disease in adult dogs”, Veterinary Microbiology, vol. 138, 2009, pp. 98-105 (Abstract). [cited by applicant]